Category Archives: Resistance to treatment

ap26113 resistance in lymphoma

Several NPM-ALK resistant mutatations were identified in the lab. They provide targets for future research. http://www.ncbi.nlm.nih.gov/pubmed/25421750

Posted in Anaplastic Large-Cell Lymphomas, brigatinib-Alunbrig from Takeda, Research, Resistance to treatment | Leave a comment

Cabozantinib overcomes crizotinib resistance in ROS1 cancer.

I know this blog is primarily about ALK inhibitors, but given that there are many similarities with ROS1, I thought I would publish this link. The researchers identified several possible secondary mutations to ROS1 after Crizotinib treatment. Cabozantinib could overcome … Continue reading

Posted in Lung cancer, Research, Resistance to treatment | Leave a comment

Update on Ariad’s drug

Second half of PowerPoint is about AP26113 http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTYxNDE4fENoaWxkSUQ9MjYwNDc2fFR5cGU9MQ==&t=1

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, Lung cancer, Research, Resistance to treatment | Leave a comment

HMS and Mass. General test new drug screening technique

“several [six] other ALK-positive tumors were re-sensitized by drugs that inhibit SRC enzymes, even though no SRC-related mutations were present. Further evidence indicated that inhibiting ALK led to activation of SRC-controlled pathways that promoted resistance. The scientists also found that … Continue reading

Posted in Lung cancer, Research, Resistance to treatment | Leave a comment

Article by Dr. Shaw on current status of ALK Inhibitor drugs

Dr. Shaw has written a comprehensive article on all 10 ALK Inhibitors being developed as of July 7, 2014. It provides comparisons of testing status, concentration levels, side effects and much more. It also includes a 2 page list of … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, CEP-37440, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Regulatory applications & approvals, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Videos by Grace from February 2014

Dr. Robert Doebele, University of Colorodo, explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments, and some do better than expected. February 2014, Published October, 2014. http://cancergrace.org/lung/?powerpress_pinw=14746-podcast For … Continue reading

Posted in Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Research, Resistance to treatment | Leave a comment

5-6 minute video by OncLive

The discussion is about Ceritinib by Novartis and AP26113 by Ariad. The main speakers are Dr. Shaw and Dr. Cambidge. https://m.youtube.com/watch?v=vRHm7XTE3fw Seems like it was recorded in May or June 2014.

Posted in Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, Lung cancer, Resistance to treatment, Side Effects | Leave a comment

Ariad AP26113 update

137 patients total, focus on phase 2 cohort of first trial of 79 patients. Early onset pulmonary symptoms reduced to 4% in phase 2. 72% objective response in phase 2. “Tumor shrinkage in nearly all patients.” 16 patients had 100% … Continue reading

Posted in brigatinib-Alunbrig from Takeda, Lung cancer, Potential Treatments, Resistance to treatment, Side Effects | Leave a comment

GRACE conference in Boston

There were several presentations as part of the Grace conference in Boston on Saturday, September 6. So far this is the only one I have found online. PowerPoint presentation by Dr. Alice Shaw on 8 or 9 new ALK inhibitors … Continue reading

Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, brigatinib-Alunbrig from Takeda, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | 1 Comment

Article on research by Dr. Alice Shaw

Here is a article about research Dr. Alice Shaw is doing on developing even newer drugs that would help slow or stop ALK tumors from developing resistance by activating other growth pathways. The research is funded by NFCR. http://www.nfcr.org/aliceshaw

Posted in Lung cancer, Research, Resistance to treatment | Leave a comment